BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer

The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.

Related Keywords

China ,Beijing ,Li Zhang ,Zhejiang ,Taiwan ,Japan ,United States ,Thailand ,America ,American ,Robert Haddad ,Junshi Bioscience ,Merck Keytruda ,Bristol Myers Squibb Opdivo ,American Society Of Clinical Oncology Plenary Series ,Drug Administration ,Novartis ,Sun Yat Sen University Cancer Center ,Oncology Congress ,European Society For Medical Oncology Immuno ,Oncology Panel ,Dana Farber Cancer Institute ,National Comprehensive Cancer Network ,American Society ,Clinical Oncology Plenary Series ,European Society ,Medical Oncology Immuno ,Seq Precision Immuno Oncology Panel ,Jiangsu Hengrui Medicine ,Bristol Myers Squibb ,North America ,